Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Biomarker Study of the Effects of Dexpramipexole on Eosinophils in Subjects With Eosinophilic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Dexpramipexole (Primary)
- Indications Asthma
- Focus Proof of concept; Therapeutic Use
- Acronyms EXHALE; EXHALE-1
- Sponsors Knopp Biosciences
- 03 Aug 2023 Results published in the Areteia Therapeutics Media Release.
- 03 Jun 2023 Results published in the Journal of Allergy and Clinical Immunology.
- 28 Feb 2022 Results of post hoc analysis presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology